CAPRICOR THERAPEUTICS, INC. CAPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
6.86
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$105.0M | — | -$72.7M | $305.8M |
| 2024 | $22.3M | -$40.5M | — | -$41.2M | $145.5M |
| 2023 | $25.2M | -$22.3M | — | -$26.9M | $22.6M |
| 2022 | $2.6M | -$29.0M | — | $2.9M | $11.8M |
| 2021 | $244,898 | -$20.0M | — | -$18.0M | $31.4M |
| 2020 | $310,250 | -$13.7M | — | -$10.6M | $28.2M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.86 (safe)
- Working capital / assets 0.807
- Retained earnings / assets -0.857
- EBIT / assets -0.304
- Equity / liabilities 6.097
Source: SEC EDGAR filings · CIK 0001133869 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.